We are a clinical-stage biotech company developing first-in-class small molecules to induce mitophagy, i.e. the process of replacing damaged mitochondria. We address age-related and chronic diseases including CNS disorders to treat cognitive impairment.
Products, services, technology
We are developing small molecules to treat unmet medical needs in the areas of CNS, lung, liver, and muscle disease. Our frontrunner CNS compound will enter clinical development by year-end 2024.
Cooperation possibilities
We are looking for potential investors for our Series B fundraise and for pharma partners for our research and development platform covering CNS, lung, liver, and muscle diseases.
- https://vandria.com/
- +41 76 615 27 26
- Send an email
- Marko Milosavljevic - Office Manager
Some insights
We are trying to address unmet medical needs in areas of high demand such as Alzheimer's Disease, and age-related muscle wasting.
Within a short time since incorporation, we have already become a clinical-stage biotech company. This achievement has only been possible thanks to our highly skilled and diverse team.
The core strengths of our team relate to the understanding of mitochondrial biology including mitophagy and the clinical development of novel medicines addressing unmet medical needs. For the future, we are looking for skills in the field of project management and regulatory services.
That we are trying to develop novel treatments for patients that currently do not have many options to cope with their diseases such as Alzheimer's Disease, or age-related muscle wasting.
By helping us to make connections to potential investors, potential partners from the pharmaceutical industry and to identify top vendors required for drug development.
